Abstract: OBJECTIV To explore the prevalence of multidrug-resistant organisms (MDROs) infections in grass-roots hospitals and analyze the prevention and management countermeasures. METHODS The patients who had infections and were treated with antibiotics from Jul 2015 to Jun 2016 were enrolled in the study. The specimens that were obtained from the patients were submitted for etiological examination.Multidrug-resistant Acinetobacter baumannii (MDRAB), extended-spectrum β-lactamases (ESBLs)-producing bacteria, carbapenem-resistant Enterobacteriaceae (CRE), and methicillin-resistant Staphylococcus aureus (MRSA) were detected by the microbiological laboratory.The drug susceptibility testing was performed for the isolated clinical strains. RESULTS A total of 4 294 specimens were submitted, of which 969 were positive, accounting for 22.56%.Totally 188 strains of MDROs were isolated, among which the proportion of ESBLs-producing Escherichia coli was the highest (56.38%), followed by the proportion of the MDRAB (12.23%) and the proportion of the MRSA (10.63%).The isolation rate of ESBLs-producing E.coli remained high, most of the MDRAB strains were isolated from ICUs, and most of the ESBLs-producing E.coli strains were isolated from internal medicine departments.The MDRAB strains were highly resistant to almost all of antibiotics.The ESBLs-producing E.coli strains were susceptible to the carbapenems such as imipenem; the carbapenem-resistant strains showed certain sensitivity to gentamicin and were highly susceptible to amikacin. CONCLUSION The clinicians should consider the actual condition of the patients and the result of drug susceptibility testing when selecting antibiotics, curb the abuse of antibiotics from various links, monitor the distribution of MDROs, and regularly analyze the change of drug resistance rate so as to provide guidance for reasonable clinical use of antibiotics.The implementation of hand hugin and disinfection and isolation measures may curb the spresd of MDRO and ensure the safety of doctors and patients.